搜索
ss
ss
关于普米斯
About Us
t12

PM1092

Our next-generation Treg depletion assets focus on targeting CCR8, which is highly upregulated on tumour-infiltrating Tregs. To improve specificity in depleting Tregs in the TME, a second arm has been targeted (CTLA-4) to minimize the depletion of CCR8- or CTLA-4-expressing effector cells such as cytotoxic CD4+ and CD8+ T cells. PM1092 has a 1+1 heterodimeric structure, where the affinities of both the CCR8- and CTLA-4-targeting arms have been optimized for binding and activity towards CCR8/CTLA-4 double-positive cells. In preclinical studies, the CCR8 x CTLA-4 bispecific has better safety than other benchmark anti-CTLA-4 mAbs, and performs better than mAbs targeting CCR8 or CTLA-4 alone for tumor inhibition.
t12
Product description
Parameters

Our next-generation Treg depletion assets focus on targeting CCR8, which is highly upregulated on tumour-infiltrating Tregs. To improve specificity in depleting Tregs in the TME, a second arm has been targeted (CTLA-4) to minimize the depletion of CCR8- or CTLA-4-expressing effector cells such as cytotoxic CD4+ and CD8+ T cells. PM1092 has a 1+1 heterodimeric structure, where the affinities of both the CCR8- and CTLA-4-targeting arms have been optimized for binding and activity towards CCR8/CTLA-4 double-positive cells. In preclinical studies, the CCR8 x CTLA-4 bispecific has better safety than other benchmark anti-CTLA-4 mAbs, and performs better than mAbs targeting CCR8 or CTLA-4 alone for tumor inhibition.

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
There is currently no content to display
Please add data record on website background.
There is currently no content to display
Please add data record on website background.

Copyright © 2022 Biotheus Inc. All Rights Reserved  粤ICP备2021122492号